Empowering Leadership Change: TPFG Appoints New CEO for Growth Initiatives
The Pacific Financial Group, Inc. Announces Organizational Changes, Charting the Course for Continued Success
Innovative SDBA Management Pioneer Sharpens Focus to Drive Operations Optimization with New CEO to Lead Next Phase of Growth
Key Leadership
We are very pleased to announce that
Former CEO,
Chris brings over two decades of leadership and business experience in the financial services space. During his 21-year tenure at Kovack Securities (FINRA B/D) and Kovack Advisors (SEC Registered RIA), he served as Executive Vice President, and then as President where he played a pivotal role in managing the day-to-day operations of both entities. He is a Certified Investment Management Analyst (CIMA) and holds multiple securities licenses. Prior to his career in finance, Chris served in the U.S. Navy for eight years.
"After an extensive search, we couldn't be happier to have Chris take the helm as our new CEO. Chris is not only a seasoned veteran of the financial industry, but a veteran of the United States Navy which is an honor for us," said
Innovation Requires Transformation
The new leadership move coincides with TPFG's continued transformation and expansion to provide financial advisors and RIAs with a cutting-edge platform for SDBA management, digital paperwork solutions, enhanced cybersecurity, and a new exclusive P4 TAMP solution.
About The Pacific Financial Group
Founded in 1984, The Pacific Financial Group, Inc. (TPFG) is a SEC registered investment advisory firm. TPFG was an early pioneer in the evolution of Self-Directed Brokerage Account (SDBA) Management for advisors helping participants with their 401(k), 403(b), and 457 accounts. www.tpfg.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/empowering-leadership-change-tpfg-appoints-new-ceo-for-growth-initiatives-302093454.html
SOURCE The Pacific Financial Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
- Edesa Biotech launches public offering of common shares
- Biodexa reaches 50% enrollment in Phase 3 FAP trial
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
The Pacific Financial GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share